Silencing of SARS-CoV-2 with modified siRNA-peptide dendrimer
formulation
Short title: Anti-SARS-CoV-2 siRNA-peptide dendrimer
formulation
Musa Khaitov1*, Alexandra
Nikonova1,2, Igor Shilovskiy1,
Ksenia Kozhikhova1, Ilya Kofiadi1,
Lyudmila Vishnyakova1, Alexander
Nikolsky1, Pia Gattinger3, Valeria
Kovchina1, Ekaterina Barvinskaya1,
Kirill Yumashev1, Valeriy Smirnov1,
Artem Maerle1, Ivan Kozlov1, Artem
Shatilov1, Anastasia Timofeeva1,
Sergey Andreev1, Olesya Koloskova1,
Ilya Sergeev1, Dmitriy Trofimov1,
Alexander Martynov, Igor Berzin4, Vladimir
Gushchin5, Aleksey Kovalchuk6,
Sergei Borisevich6, Rudolf
Valenta1,3, Rakhim Khaitov1 and
Veronica Skvortsova4
1 NRC Institute of Immunology FMBA, Moscow, Russia
2 Mechnikov Research Institute for Vaccines and Sera,
Moscow, Russia
3 Medical University of Vienna, Vienna, Austria
4 Federal Medico-biological Agency of Russia (FMBA
Russia)
5 Federal State Budget Institution “National Research
Centre for Epidemiology and Microbiology named after Honorary
Academician N. F. Gamaleya” of the Ministry of Health of the Russian
Federation, Moscow, Russia
6 48 Central Research Institute of the Ministry of
Defense of the Russian Federation, Moscow, Russia
* Corresponding author